An interventional study of Abluminus DES+ Sirolimus Eluting Stent System (SES) and XIENCE Everolimus Eluting Coronary Stent System (XIENCE family) in Diabetes, Coronary Artery Disease and Acute Coronary Syndrome, sponsored by Concept Medical Inc.. Completed at 90 sites in 21 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Concept Medical Inc. · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 270 studies in Diabetes Mellitus with a site in Italy — 31 open to participants now, 42 under way, 3 of them phase 3. Diabetes Mellitus · Italy.
Among the 270 studies in Diabetes Mellitus with a site in Italy, this one is the 16th largest by enrollment of the 201 interventional ones that give a count, is one of 11 that started in 2020, is one of 64 with no phase, and was the 201st registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →31 of the 270 studies in Diabetes Mellitus with a site in Italy are open now. Recruiting first, the newest first:
Pfizer · Sites in Italy, United States, Brazil and 8 more countries
Ages 18+
Ospedale San Raffaele · Sites in Italy
Ages 12–70 · Healthy volunteers
University of Roma La Sapienza · Sites in Italy
Ages 18+ · Healthy volunteers
IRCCS San Raffaele · Sites in Italy
Ages 18+
Fondazione Policlinico Universitario Campus Bio-Medico · Sites in Italy
Ages 18+ · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
270 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 29 · Phase 3 85 · Phase 4 31
First in 1994; this study’s year is marked. 11 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,050 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 300 across the 201 interventional studies, 406 across the 67 observational. Of the 193 that completed or were terminated, 68 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 270 have an industry lead sponsor. The 10 most frequent:
Concept Medical Inc. is the lead sponsor of 9 studies on the registry; 7 are open to participants now.
Concept Medical Inc. has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
7 of the studies in Diabetes Mellitus with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07206875IRCCS San RaffaeleObservational Study for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine Disorders | 2026-11 |
| NCT07119424Chiara LanzaniMultidisciplinary Dissection of Renal and Metabolic Effects of Glyfozines on Elderly Patients: From Molecular Aspects to Clinical Indications | 2026-11 |
| NCT07604493University of Roma La SapienzaOral Health and Systemic Diseases: Survey of General Practitioners | 2026-11-30 |
| NCT07783893Marche Region Regional Health AgencyE-Health Literacy Intervention for Bangladeshi Migrants With Type 2 Diabetes in Italy | 2026-12 |
| NCT06801769Catholic University of the Sacred HeartStudy for the Identification of a Score to Assess Intrapancreatic Fat Through Eco-Elastography and Its Correlation With Metabolic Syndrome and Insulin-Secreting Cells. | 2026-12 |
Add all 7 to your calendar (.ics) → With an account.
Among the 270 studies in Diabetes Mellitus with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare in diabetic patients eligible for percutaneous coronary intervention (PCI) with minimal exclusion criteria, the efficacy and safety of Abluminus DES+ sirolimus- eluting stents (SES) versus XIENCE Everolimus-Eluting Stents (EES). At least 40% of patients are expected to be affected by multivessel coronary artery disease and 30% with acute coronary syndrome
This study aims to determine which DES will best treat the diabetic population. Specifically, the research question of this trial is to evaluate the use of a novel sirolimus-eluting stent coated with drug-eluting polymer after crimping on the balloon as compared to the standard-of-care EES in the treatment of de novo coronary artery disease in patients with diabetes mellitus. ABILITY is a prospective, multi-center, multinational, randomized, open label, 2-arm parallel group, post-approval study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical Inclusion Criteria
Diabetic patient: either:
i. Fasting plasma glucose (FPG) ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for ≥8 hours1 or ii. Two-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) following a 75g oral glucose tolerance test or iii. level ≥ 7% (53 mmol/mol) Patients who are newly diagnosed are included even if they are not on pharmacological treatment (oral hypoglycemic agents or insulin)
Patient is willing and able to comply with all protocol-required follow-up evaluations.
Angiographic Inclusion Criteria (visual estimate)
Exclusion Criteria:
Clinical Exclusion Criteria
Currently participating in another drug or device study.
Angiographic Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enrolled patients will undergo angioplasty with Abluminus DES+ sirolimus- eluting stents (SES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the Abluminus DES+ sirolimus- eluting stents (SES).
Device: Abluminus DES+ Sirolimus Eluting Stent System (SES)
Enrolled patients will undergo angioplasty with XIENCE Everolimus-Eluting Stents (EES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the XIENCE Everolimus-Eluting Stents (EES).
Device: XIENCE Everolimus Eluting Coronary Stent System (XIENCE family)
The Sirolimus-eluting stent manufactured by Envision and distributed by Concept Medical
The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA
Rate of Ischemia-driven TLR
powered for non-inferiority and sequentially superiority
Time frame: 1 year FU
Rate of Target lesion failure TLF
composite of cardiovascular death, target vessel myocardial infarction \[MI\], or ischemia driven target lesion revascularization \[idTLR\])
Time frame: 1 year FU, powered for non-inferiority
Safety composite endpoint
Safety composite endpoint of the occurrence of cardiovascular death and target-vessel myocardial infarction (MI)
Time frame: 1 year (non-inferiority)
co-primary TLR endpoint
In case the co-primary TLR endpoint (TLR for non-inferiority) will be demonstrated at 1 year, then the occurrence of ischemia-driven TLR at 2-year FU will be evaluated (efficacy endpoint - superiority)
Time frame: 2 Year FU
Composite of cardiovascular death, target vessel MI and ischemia-driven TLR (TLF)
Cardiovascular death is defined as death resulting from cardiovascular causes. The following categories may be collected: 1. Death caused by acute MI 2. Death caused by sudden cardiac, including unwitnessed, death 3. Death resulting from heart failure 4. Death caused by stroke 5. Death caused by cardiovascular procedures 6. Death resulting from cardiovascular hemorrhage 7. Death resulting from other cardiovascular cause Any MI not clearly attributable to a non-target vessel will be considered as target-vessel MI. * Percutaneous coronary intervention (PCI) related MI is termed type 4a MI. * Coronary artery bypass grafting (CABG) related MI is termed type 5 MI. Revascularization is clinically driven if the target lesion diameter stenosis is \> 50% by quantitative coronary angiography (QCA) and the subject has clinical or functional ischemia which cannot be explained by another native coronary or bypass graft lesion.
Time frame: 1 year FU
Bleeding
Bleeding BARC 2 or greater
Time frame: 2 year
Composite of cardiovascular death, target vessel MI and ischemia-driven TLR (TLF)
Cardiovascular death is defined as death resulting from cardiovascular causes. Any MI not clearly attributable to a non-target vessel will be considered as target-vessel MI. Revascularization is clinically driven if the target lesion diameter stenosis is \> 50% by quantitative coronary angiography (QCA) and the subject has clinical or functional ischemia which cannot be explained by another native coronary or bypass graft lesion.
Time frame: 2 year FU
Occurrence of cardiovascular death and target-vessel myocardial infarction (MI)
Cardiovascular death is defined as death resulting from cardiovascular causes. The following categories may be collected: 1. Death caused by acute MI 2. Death caused by sudden cardiac, including unwitnessed, death 3. Death resulting from heart failure 4. Death caused by stroke 5. Death caused by cardiovascular procedures 6. Death resulting from cardiovascular hemorrhage 7. Death resulting from other cardiovascular cause. Any MI not clearly attributable to a non-target vessel will be considered as target-vessel MI. * Percutaneous coronary intervention (PCI) related MI is termed type 4a MI. * Coronary artery bypass grafting (CABG) related MI is termed type 5 MI.
Time frame: 2 year
All-cause mortality
all deaths are considered cardiovascular unless an alternate cause is unequivocally established, even among subjects with serious noncardiac comorbidities.
Time frame: up to 2 years from procedure
Stroke
according to Neuro-ARC stroke/TIA criteria
Time frame: up to 2 years from procedure
Stent thrombosis
defined for grade and timing according to the Academic Research Consortium2
Time frame: 2 year
Technical success
Technical success is defined as the ability to cross the occluded segment with both a wire and a balloon, and successfully open the artery; the restoration of antegrade TIMI flow 2 or 3 and a \<30% residual stenosis. (As applies to chronic total occlusion - CTO - lesions)
Time frame: 2 year
Clinical procedural success
In the case of percutaneous intervention for obstructive lesions, procedural success is defined as the achievement of a final residual diameter stenosis \< 30% by angiography at the end of the procedure (and without flow limiting arterial dissection and hemodynamically significant translesional pressure gradient) without any in-hospital major adverse events (death, acute onset of limb ischemia, need for urgent/emergent vascular surgery). The balloon inflation and/or stent placement may be preceded by use of adjunctive devices (e.g., percutaneous mechanical thrombectomy, directional or rotational atherectomy, laser, chronic total occlusion crossing device). Ideally, the assessment of the residual stenosis at the end of the procedure should be performed by an angiographic core laboratory.
Time frame: 2 year
Occurrence of ischemia-driven TLR
Revascularization is clinically driven if the target lesion diameter stenosis is \> 50% by quantitative coronary angiography (QCA) and the subject has clinical or functional ischemia which cannot be explained by another native coronary or bypass graft lesion.
Time frame: 2 year FU
Target vessel revascularization (TVR)
TLR is a repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.
Time frame: up to 2 years
Plan to share: No
Ran from Jun 2020 to primary completion in Nov 2023, 41 months.
Of 160 industry-sponsored interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 41 months is above that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Oct 2023 → Nov 2023 and completion Sep 2024 → Nov 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Concept Medical Inc.